Circulating tumor cells (CTCs) enter peripheral blood from primary tumors and seed metastases. 
Reproducible Copy Number Variation Patterns among Single Circulating Tumor Cells of Lung Cancer Patients

Introduction
As a genomic disease, cancer involves a series of changes in the genome, starting from primary tumors, via circulating tumor cells (CTCs), to metastases that cause the majority of mortalities (1) (2) (3) . These genomic alterations include copy number variations (CNVs), single nucleotide variations (SNVs), and insertions/deletions (INDELs). Regardless of the concentrated efforts in the past decades, the key driving genomic alterations responsible for metastases are still elusive (1) .
For non-invasive prognosis and diagnosis of cancer, it is desirable to monitor genomic alterations through the circulation system. Genetic analyses of cell-free DNA fragments in peripheral blood have been reported (4-6), and recently extended to the whole genome scale (7) (8) (9) .
On the other hand, it may be advantageous to analyze CTCs, as they represent intact functional cancer cells circulating in peripheral blood (10) . While previous studies have shown that CTC counting was able to predict progression and overall survival of cancer patients (11, 12) , genomic analyses of CTCs could provide more pertinent information for personalized therapy (13) .
However, it is difficult to probe the genomic changes in DNA obtainable from the small number of captured CTCs. To meet this challenge, a single cell whole genome amplification (WGA) method, MALBAC (14) , has been developed to improve the amplification uniformity across the entire genome over previous methods (15, 16) , allowing precise determination of CNVs and detection of SNVs with a low false positive rate in a single cell. Here we present genomic analyses of CTCs from 11 patients (SI Appendix, Table S1 ) with lung cancer, the leading cause of worldwide cancer-related deaths. CTCs were captured with the CellSearch platform using antibodies enrichment after fixation, further isolated with 94% specificity (Materials and Methods), and then subjected to WGA using MALBAC prior to next generation sequencing. heterogeneous from cell to cell, as previously reported for solid tumors (16, 17) . 6 We now focused on those SNVs/INDELs reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) (18) , which may play critical roles in cancer. In Patient 1, all COSMIC mutations that appeared in the primary and/or metastatic tumors have been detected in CTCs, as shown in the Venn diagram (Fig. 2C ). Among these mutations, one INDEL in the epidermal growth factor receptor (EGFR) gene (p.Lys746_Ala750del), which is a target for tyrosine kinase inhibitors (TKIs) (19) , was identified in the primary and metastatic tumors as well as in CTCs.
This illustrated an example for the utility of CTC sequencing for identifying therapeutic target for personalized treatment.
The other three COSMIC mutations in the phosphatidylinositol 3-kinase catalytic subunit α (PIK3CA) (p.Glu545Lys), tumor protein 53 (TP53) (p.Thr155Ile), and retinoblastoma (RB1) (p.Arg320*) genes were only shared between the liver metastatic tumor and CTCs. The fact that these three mutations were not detected in the primary tumor was due to their low abundance.
Indeed, the use of PCR amplification together with deep sequencing revealed these mutations in the primary tumor (SI Appendix, Fig. S2 ). Regardless of its low abundance in the primary tumor, the PIK3CA mutation was detected in 7 of 8 CTCs from Patient 1. The PIK3CA mutation has been implicated in drug resistance of erlotinib (20) . Consistently, Patient 1 underwent rapid disease progression in the liver metastasis after one-month of EGFR TKI treatment with erlotinib.
Concurrent mutations in RB1 and TP53 were commonly found in SCLC (21) and have been reported to be able to efficiently transform other cells to SCLC (22) . We observed RB1 and TP53 mutations in most of the CTCs in this lung ADC patient. Subsequent needle-biopsy of the liver confirmed this transition ( those of the primary tumor, raising the possibility that our captured CTCs came from the metastatic tumor. However, we observed that EGFR mutation was homozygous in bulk sequencing of the liver metastatic tumor, but was 50% heterogeneous in the eight CTCs. A mixture of wild-type and homozygous mutant genotypes led to an appearance of heterozygous 8 EGFR mutations in the primary tumor. The EGFR mutation frequency in CTCs is close to that in the primary tumor, suggesting that a large proportion of CTCs originated from the primary tumor and were in an intermediary for metastasis. Furthermore, both primary and metastatic tumors had more than 70% of tumor cell content (SI Appendix, Table S1 ), which excluded the possibility of low tumor content in complicating our observation.
Our finding suggests that during the metastatic process gain and loss of copy numbers at certain chromosome regions are selected for cancer cells to enter or survive in the circulation system, becoming CTCs. The reproducible CNV patterns might come from the possibility that
CTCs originated from one subclone in the primary tumor or due to the CTC selection criterion.
This is unlikely given the heterogeneity of SNVs in single CTCs.
We examined the reproducibility of the CNV patterns among five other patients (Patients identical global CNV patterns is striking, providing not only the basis for potential diagnosis of ADC via CTCs, but also clues for metastasis. 9 We listed the common copy number gain (in >16 CTCs) and loss (in >7 CTCs) regions, together with some important cancer-related genes, of the 5 ADC patients' CTCs in SI Appendix, A broad survey of CNV patterns in CTCs of different cancers is underway to examine whether the same degree of reproducibility also occurs in other types of cancers. Although the underlying molecular mechanism is yet to be illustrated, the observation of reproducible genomic alterations is highly instructive for the understanding of metastasis or even genesis of cancer.
The reproducible CNV patterns that are characteristic of different cancers might allow non-invasive cancer diagnostics and classification through sequencing of CTCs.
Materials and Methods
This study was approved by the institutional ethics committee at Peking University Cancer Table S3 .
Whole Genome Library Preparation and Sequencing. Libraries for whole genome sequencing were prepared from the adaptor-ligated DNA before the pooling step in exome library preparation. Enrichment PCR was performed on an aliquot of adaptor-ligated DNA to complete the adaptor for Illumina PE sequencing. The PCR product was quality checked and sequenced with Illumina HiSeq 2000/2500 2×100 bp PE reads or MiSeq 300 2×150 bp PE reads at ~0.1x sequencing depth. The cost for this low sequence depth is affordable for clinical study.
Exome Sequencing Data Analysis for SNVs/INDELs. Sequencing reads were aligned to the UCSC human reference genome (hg19) using the Burrows-Wheeler Aligner (BWA) (35). The aligned reads were sorted and merged with Samtools 0. Clustering Analysis. Clustering analysis based on the whole genome CNVs was applied to distinguish CTCs from different patients using algorithms implemented in R package (http://www.R-project.org). First, we normalized sequence reads of each CTC with sequence reads from all normal leukocytes to remove whole genome amplification bias. We then determined the copy number sequence (a1, a2, a3,…; b1, b2, b3,…;…) at a bin size of 500K along the genome by comparing the normalized reads with reads from diploid regions found by HMM.
The Euclidean distance between pairs of copy number sequence of CTCs was calculated by:
where a and b represent different CTCs. 'i' is the index for the bins.
Based on the above Euclidean distances, Ward's linkage criterion (41, 42) was applied to create clusters of CTCs (Fig. 3C ).
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